Lorlatinib/Lorlatinib Dosing Guidelines

Lorlatinib Lorlatinib is a drug designed to treat adults with metastatic non-small cell lung cancer (NSCLC), especially those whose tumors are confirmed to be anaplastic lymphoma kinase (ALK) positive by an FDA-approved test. When a patient's tumor specimen tests positive for ALK, the doctor may recommend treatment with lorlatinib. However, it should be noted that lorlatinib is contraindicated in patients who are taking strong CYP3A inducers due to the possible risk of severe hepatotoxicity.

The recommended dose of lorlatinib is 100 mg daily taken by mouth as a single dose with or without food. Patients should continue taking this drug until disease progression or unacceptable toxicity occurs. Lorlatinib is available in tablet form, and patients should swallow the tablet whole and try to take it at the same time every day. Avoid chewing, crushing, or splitting tablets. Do not take any tablets that are damaged, cracked, or incomplete. If the patient misses a dose, the missed dose should be taken as soon as possible, but if the next dose will be taken within 4 hours, there is no need to take the missed dose.

During lorlatinib treatment, if a patient experiences adverse reactions, the doctor will adjust the drug dose based on the severity of the symptoms. The first adjustment can reduce the dose to 75 mg daily, and if further reduction is needed, it can be adjusted to 50 mg daily. For those patients who are unable to tolerate the 50 mg daily dose, lorlatinib should be permanently discontinued. In any case, if lorlatinib needs to be used in combination with other drugs, it should be done under the guidance of a physician, and the dose of lorlatinib may need to be adjusted.